文献速递临床试验与 GCP真实世界研究与卫生经济

OneSTOP研究方案:远程医疗与数字平台用于体重管理及共病多学科管理的开放标签随机对照试验

OneSTOP (One-Stop Telehealth Obesity Program): study protocol for an open-label randomized controlled trial on the use of telecare and digital platforms for multidisciplinary management of weight management and related comorbidities.
PubMed 文献 · Trials · 2026-03-24

OneSTOP是一项单中心开放标签随机对照试验方案,比较远程医疗联合EMPOWER应用与标准面对面体重管理项目,纳入肥胖伴糖尿病和MASLD成人,主要终点为26周体重变化百分比。

要点

  • 远程医疗组接受面对面与远程咨询联合EMPOWER应用进行饮食运动记录和行为提醒。
  • 主要终点为26周体重变化百分比,次要终点包括体重降低≥5%比例、HbA1c和MASLD严重程度。
  • 对照组为指南推荐的标准面对面医生和营养师体重管理项目。

核心结论

  • 该方案旨在评估远程医疗联合数字应用对肥胖伴糖尿病和MASLD患者体重及相关共病的管理效果。

研究设计与样本

  • 单中心开放标签随机对照试验,设两个研究组:远程医疗联合EMPOWER应用组与标准面对面体重管理对照组。
  • 研究对象为肥胖伴糖尿病和MASLD的成人,方案已注册于ClinicalTrials.gov(NCT06890169)。

主要发现

  • 原文为研究方案,未报告研究结果。

关键数值与推荐

  • 主要结局为26周体重变化百分比。
  • 次要结局包括26周体重降低至少5%的受试者比例。
  • 次要结局包括12周和26周HbA1c所测血糖控制改善。
  • 次要结局包括26周通过肝功能检查和影像无创测量肝脂肪变性和纤维化的MASLD严重程度。

临床怎么用

  • 为显著肥胖相关并发症患者提供一站式体重管理方案,尤其针对MASLD人群探索远程医疗和数字疗法用于生活方式干预。

局限性

  • 原文为研究方案,尚未报告研究结果,无法评估干预效果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Obesity is prevalent in Singapore and is a driver of multiple co-morbidities including type 2 diabetes, metabolic dysfunction associated steatotic liver disease (MASLD), and cardiovascular disease. Traditional weight management programs have drawbacks of minimal contact with patients in between appointments leading to loss of motivation, patients defaulting appointments, and non-compliance to treatment regimes. While there is a plethora of apps for lifestyle modification and health messaging, there is an unmet need for a one-stop weight management program for patients with significant obesity-related complications, particularly MASLD, where there have been relatively few studies to date on the use of telemedicine and digital therapies for lifestyle intervention. METHODS: This is a single-center open-label randomized controlled trial with two study arms-Telehealth + EMPOWER app care model vs control arm which comprises of a standard weight management program of face-to-face (F2F) consults with doctors and dieticians as defined by best-practice guidelines for inducing clinically significant metabolic improvements in obese adults with diabetes mellitus and MASLD. Patients in the telehealth arm will receive a combination of face-to-face consultations and tele-consults in addition to access to the EMPOWER app, which can be used for food and exercise diary and can provide users reminders and nudges on behavioral changes. The primary outcome in our study is percentage change in weight at 26 weeks. Secondary outcomes are percentage of subjects with reduction in weight of at least 5% at 26 weeks, improvement in glycemic control (as measured by HbA1c) at 12 and 26 weeks, and severity of MASLD using liver function tests and imaging to measure hepatic steatosis and fibrosis non-invasively at 26 weeks. DISCUSSION: Obesity, DM, and MASLD carry significant healthcare costs and weight loss of 5-10% improves glycemic control and thus decreases macro- and microvascular complications of diabetes and can significantly decrease the severity of liver disease in as little as 6 months to a year. TRIAL REGISTRATION: ClinicalTrials.gov NCT06890169. Registered on March 17, 2025. https://clinicaltrials.gov/study/NCT06890169?term=NCT06890169&rank=1.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Khoo J, Leong AT, Rahul K, et al. OneSTOP (One-Stop Telehealth Obesity Program): study protocol for an open-label randomized controlled trial on the use of telecare and digital platforms for multidisciplinary management of weight management and related comorbidities. Trials. 2026. PMID: 41877269. doi:10.1186/s13063-026-09655-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。